{
  "ticker": "CMB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968465",
  "id": "02968465",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250711",
  "time": "0910",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250711/pdf/06lpy44g9n1jdv.pdf",
  "summary": "- **FDA clearance** obtained to initiate **Phase 3 trials** for **Elate Ocular\u00ae** in **dry eye disease (DED)**.  \n- **Trials (CAMOMILE-2 & CAMOMILE-3)** pending **additional financing**; company in **funding discussions**.  \n- No specific capital raise or financial figures disclosed.  \n\n*Material focus: Regulatory milestone de-risks Phase 3 progress, but financing remains a key hurdle.*",
  "usage": {
    "prompt_tokens": 1121,
    "completion_tokens": 98,
    "total_tokens": 1219,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-10T23:20:46.631431"
}